KBC Group’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

KBC Group’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-520	Closed	-$104K	–	1346
2021 Q3	$104K	Sell	520 -520	-50%	-$124K	﹤0.01%	1156
2021 Q2	$266K	Buy	1,040 +487	+88%	+$122K	﹤0.01%	1137
2021 Q1	$146K	Hold	553	–	–	﹤0.01%	1216
2020 Q4	$1.12M	Hold	553	–	–	﹤0.01%	1129
2020 Q3	$136K	Hold	553	–	–	﹤0.01%	1158
2020 Q2	$160K	Buy	553 +330	+148%	+$97.3K	﹤0.01%	1178
2020 Q1	$46K	Hold	223	–	–	﹤0.01%	1207
2019 Q4	$100K	Sell	223 -119	-35%	-$42.2K	﹤0.01%	1356
2019 Q3	$105K	Buy	+342	New	+$111K	﹤0.01%	1330

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAWC

P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

KBC Group's EIGR Position: Q4 2021 in Review

KBC Group sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2021, closing a stake of 520 shares — an estimated $104K sold.

KBC Group first reported a position in EIGR in Q3 2019 and held it in 9 quarters. The position peaked at $1.12M in Q4 2020. 85 funds tracked by Wall St. Rank hold EIGR as of Q4 2021.

KBC Group reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
KBC Group sold 520 Eiger BioPharmaceuticals, Inc. shares in Q4 2021, an estimated $104K.
KBC Group first reported a position in Eiger BioPharmaceuticals, Inc. in Q3 2019 and held it in 9 quarters.
KBC Group's Eiger BioPharmaceuticals, Inc. position peaked at $1.12M in Q4 2020.
85 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2021.

Based on KBC Group's 13F filing for Q4 2021, filed 3 Feb 2022.